Glaxo submits sNDA for Promacta expanded label
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 10:48AM CST
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta(R)
Business Wire - Mon Dec 22, 8:20AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
Update: Ligand Wins EU Approval For Duavive
Trevor Lowenthal - at Seeking Alpha - Sun Dec 21, 9:02AM CST
PFE: 31.42 (-0.03), LGND: 51.79 (+1.22)
Ligand earns milestone payment on EU approval of Duavive
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:48AM CST
PFE: 31.42 (-0.03), LGND: 51.79 (+1.22)
Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE(R) (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus
Business Wire - Fri Dec 19, 10:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Pfizer has received EU marketing authorization for DUAVIVE(R) (conjugated estrogens/bazedoxifene (BZA/CE)) from the European Commission. In the EU, DUAVIVE(TM) is indicated for the treatment of estrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. Ligand will be entitled to a milestone payment following Pfizer obtaining pricing of DUAVIVE(R) in a major European market.
LGND: 51.79 (+1.22)
Ligand Pharmaceuticals: Investor Day Highlights The Big 6, All Undervalued Catalysts
Chris Katje - at Seeking Alpha - Mon Nov 24, 8:04AM CST
LGND: 51.79 (+1.22)
Ligand Provides Highlights from Today's Analyst Day Event
Business Wire - Tue Nov 18, 10:41AM CST
At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the financial leverage in its business model, revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs, as well as its Captisol formulation technology and its financial outlook through 2017.
LGND: 51.79 (+1.22)
Ligand Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Tue Nov 18, 9:44AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 1 month, Ligand Pharmaceuticals has returned 17.21% as of today's recent price of $57.25.
LGND: 51.79 (+1.22)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 51.79 (+1.22), ILMN: 186.22 (+2.72), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48)
Glaxo applies for Revolade label expansion in Europe
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:01AM CST
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade(TM) (eltrombopag)
Business Wire - Wed Nov 12, 8:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade(TM) (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:22AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 51.79 (+1.22)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CNAT: 6.84 (+0.17), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 51.79 (+1.22)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)